SDI.TO Stock News Spectral Diagnos (SDI.TO) 0.38 08/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Spectral Diagnos (SDI.TO) 0.38 $SDI.TO

Spectral Diagnostics and Toray Industries announce closing of Tranche "A" component of its up to $18.2 million Offering
CNW Group - Fri Jul 25, 8:26AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or"Spectral"and Toray Industries, Inc. ("Toray" today announced the closing of Tranche "A" of the previously announced non-brokered private placement of the Corporation (the "Offering". The Tranche "A" component of the Offering was comprised of 45,051,186 common shares of the Corporation ("Shares",at a subscription price of $0.293 per Share for aggregate proceeds of $13.2 million. The Offering was approved by shareholders of the Corporation at a special meeting of shareholders held on July 22, 2014.

Spectral Diagnostics announces shareholder approval of its up to $18.2 million offering
CNW Group - Tue Jul 22, 1:26PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral" today announced that at the special meeting (the "Special Meeting" of shareholders ("Shareholders" of the Corporation held earlier today, Shareholders overwhelmingly approved the terms of the previously announced proposed non-brokered private placement of the Corporation of up to $18.2 million (the "Offering".

Spectral Announces ISS and Glass Lewis Recommendations to Vote in Favour of its up to $18.2 Million Offering
CNW Group - Tue Jul 08, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral" today announced that both ISS Proxy Advisory Services and Glass Lewis & Co. have endorsed the previously announced non-brokered private placement of the Corporation of up to $18.2 million (the "Proposed Offering" and recommend that shareholders of Spectral ("Shareholders" vote "FOR" the Proposed Offering at the upcoming special meeting of Shareholders to be held on July 22, 2014.

Spectral Diagnostics announces Proposed Offering of up to $18.2 million
CNW Group - Wed Jun 11, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced it has entered into agreements for a non-brokered private placement of up to $18.2 million (the "Proposed Offering".

U.S. FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial
CNW Group - Tue Jun 03, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF) ("Spectral" or the "Company", a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the U.S. Food and Drug Administration (FDA) has approved the amended protocol for its EUPHRATES trial, reflecting the recommendations of the Data Safety Monitoring Board (DSMB) of April 9, 2014. The DSMB recommended an additional exclusion criterion be added to the clinical protocol and that the sample size should be increased to 650 patients.

Spectral announces fourth quarter and fiscal 2013 results
CNW Group - Thu Mar 27, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its audited financial results for the fourth quarter and year ended December 31, 2013.

Spectral Diagnostics Provides Clinical Update on the Euphrates Trial
CNW Group - Tue Mar 11, 4:00PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF) ("Spectral" or the "Company", a Phase III company developing the first theranostic treatment for patients with septic shock today announced an update on its ongoing EUPHRATES trial.

Spectral Diagnostics Announces Extension of Warrants
CNW Group - Mon Feb 24, 6:00AM CST
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced that its board of directors has approved an extension of the expiry date of the outstanding 24,375,000 common share purchase warrants and 731,250 broker warrants of the Corporation (collectively, the "Warrants" from March 2, 2014 to September 2, 2014. The exercise price of the Warrants remains unamended at $0.60 and no other changes were made to the terms of the Warrants. The Warrants were issued in connection with a previous financing of the Corporation.

Spectral announces status of second interim analysis
CNW Group - Tue Jan 28, 6:00AM CST
Spectral Diagnostics Inc. (TSX:SDI) (OTCQXIAGF) ("Spectral" or the "Company", a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that the Data Safety Monitoring Board (DSMB) has evaluated the safety, efficacy and futility of its EUPHRATES trial based on actual data for 184 randomized patients followed for 28 days.

Spectral announces second quarter 2013 results
CNW Group - Tue Aug 13, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2013.

Spectral to present at Wedbush Life Sciences Conference
CNW Group - Thu Aug 01, 9:30AM CDT
Spectral Diagnostics Inc., (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that the Company's President and CEO, Dr. Paul Walker, will be presenting a corporate overview at the Wedbush Life Sciences Management Access Conference in New York on Wednesday, August 14, 2013, at 1:20 p.m. ET.

Spectral provides update on its EUPHRATES trial
CNW Group - Wed Jul 31, 6:00AM CDT
- Trial is on track and continues to enroll patients at an accelerated rate -

Spectral Diagnostics Announces Board Changes
CNW Group - Fri Jul 26, 4:00PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced that Mr. Ian Lennox and Mr. Ed McCormack have resigned as directors of the Corporation, effective August 1, 2013.

Spectral Diagnostics provides update on results of annual and special meeting
CNW Group - Thu May 23, 10:10PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced that Mr. Anthony Bihl has been appointed as the Chairman of the board. The Corporation also notes that at the annual and special meeting of shareholders that was held earlier today, all eight nominees for the board were elected as a matter of corporate law, however, two of the directors received a greater number of votes withheld than votes in favour. Pursuant to the Majority Voting Policy of the Corporation, those two directors have each tendered their resignations as directors, effective only on acceptance by the board. Full details are contained in the Report of Voting Results for the Meeting which has been filed on Sedar at www.Sedar.com.

Spectral announces first quarter 2013 results
CNW Group - Wed May 15, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI / OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced its unaudited financial results for the first quarter ended March 31, 2013.

Spectral Appoints Vice President of Sales and Marketing
CNW Group - Tue May 07, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI / OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the appointment of Dr. Gualtiero Guadagni as the Company's Vice President, Sales and Marketing.

Spectral Diagnostics adopts new By-Laws which contain advance notice provisions
CNW Group - Tue Apr 16, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) ("Spectral", or the "Corporation" today announced the approval and adoption by its board of directors (the "Board" of new by-laws ("By-Laws" which include advance notice provisions, the purpose of which is to require advance notice be provided to the Corporation in circumstances where nominations of persons for election to the Board are made by shareholders of the Corporation other than pursuant to: (i) a requisition of a meeting of shareholders made pursuant to the provisions of the Business Corporations Act (Ontario) (the "Act"; or (ii) a shareholder proposal made pursuant to the provisions of the Act.

Spectral Diagnostics Closes $5.6 Million Offering
CNW Group - Tue Apr 02, 6:00AM CDT
- Toray Industries, Inc. Subscribes for $5 Million of Offering -

Spectral Diagnostics increases offering to $5.6 million
CNW Group - Mon Mar 18, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) ("Spectral", or the "Company" today announced that it has increased the size of its previously announced private placement to an aggregate $5.6 million, comprised of a total of 18,666,667 common shares in the capital of the Company ("Common Shares", at a price of $0.30 per Common Share (the "Private Placement".
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading